<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104351">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02076061</url>
  </required_header>
  <id_info>
    <org_study_id>KOL 001</org_study_id>
    <nct_id>NCT02076061</nct_id>
  </id_info>
  <brief_title>Biomarkers of Early Chronic Obstructive Pulmonary Disease (COPD) in Smokers - Longitudinal Study</brief_title>
  <official_title>Biomarkers of Early Chronic Obstructive Pulmonary Disease (COPD) and Cardiovascular Diseases in Smokers/Ex-Smokers Attending Primary Care - Longitudinal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Örestadskliniken</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a longitudinal observational study to identify and validate protein biomarkers for
      COPD (chronic obstructive pulmonary diseases) and cardiovascular disease in smokers and
      ex-smokers attending primary care.  Special emphasize is to correlate biomarkers to
      different phases of COPD, to progression of the disease, and to treatment of the disease.
      Furthermore, linkage between COPD, cardiovascular disease, and lung cancer will be
      investigated by identifying protein biomarkers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Advanced disease etiology requiring hospitalization.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>GOLD stage I</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>GOLD Stage II</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>GOLD Stage III</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>GOLD Stage IV</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Smokers/ex-smokers w/o COPD</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>non-Smokers w/o COPD</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic in Malmö, Sweden
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosed with COPD Gold stage 0-IV

        Exclusion Criteria:

        Patients with inflammatory diseases Patients with cancer Patients using immune system
        regulating drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan Malm</last_name>
    <role>Study Chair</role>
    <affiliation>Clincal Chemistry, Lund University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>György Marko-Varga</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Protein Science &amp; Imaging, Lund University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mikael Truedsson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Örestadskliniken Malmö</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisabet Wieslander</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Oncology and Pathology, Lund University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas E Fehniger</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Protein Science &amp; Imaging, Lund University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magnus Dahlbäck</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Protein Science &amp; Imaging, Lund University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger Appelqvist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Protein Science &amp; Imaging, Lund University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikael Truedsson</last_name>
    <phone>+4640163200</phone>
    <email>mikael.truedsson@orestadskliniken.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Örestadskliniken</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikael Truedsson</last_name>
      <phone>+4640163200</phone>
      <email>mikael.truedsson@orestadskliniken.com</email>
    </contact>
    <contact_backup>
      <last_name>Martin Wiklund</last_name>
      <phone>+4640163200</phone>
      <email>martin.wiklund@orestadskliniken.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mikael Truedsson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>February 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lund University</investigator_affiliation>
    <investigator_full_name>Johan Malm</investigator_full_name>
    <investigator_title>Professor, Clincal Chemistry</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Primary Care</keyword>
  <keyword>Smoking</keyword>
  <keyword>Smokers</keyword>
  <keyword>ex-Smokers</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Proteomics</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Biobank</keyword>
  <keyword>Disease Staging</keyword>
  <keyword>Gold Stage</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
